Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

 

Reality Check on Psoriatic Arthritis

Market access for psoriatic arthritis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 70% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In September 2020, the FDA expanded the use of the Janssen Pharmaceutical Companies of Johnson & Johnson's Simponi Aria (golimumab) for people at least 2 years of age for the treatment of active polyarticular juvenile idiopathic arthritis and expanded the active psoriatic arthritis indication to the same patient population
  • Key Findings: New-to-market products will have to compete with a crowded market of recently approved biosimilars and their reference products, which currently occupy preferred status on most plans, as well as brand-only disease-modifying antirheumatic drugs

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.

MMIT-RC_Thumbnail_1-1.png